We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

MorphoSys and Pfizer’s Antibody Development Deal Expanded for Three Years

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
MorphoSys has announced that it has expanded its collaboration with Pfizer for the development of antibody therapeutics by three years.
 
The agreement builds upon a deal struck in 2003 scheduled to end in 2008. The new deal extends the collaboration to 2011 and includes a one-off payment from Pfizer, MorphoSys said.
 
Under the agreement, MorphoSys, based in Martinsried, Germany, will use its HuCAL Gold human combinatory antibody library to generate therapeutic antibodies against targets supplied by Pfizer, which Pfizer will then take to preclinical and clinical trials.
 
MorphoSys said the agreement offers potential royalties and milestone payments from resulting product sales.
 
Financial terms of the agreement were not released.